Menu
Back to User profile » Dr David A Lipson
Papers published by Dr David A Lipson:
Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
Panettieri Jr RA, Camargo CA Jr, Cheema T, El Bayadi SG, Fiel S, Vila TM, Jain RG, Midwinter D, Thomashow B, Ludwig-Sengpiel A, Lipson DA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:2043-2052
Published Date: 1 September 2022
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
Gabrio A, Gunsoy NB, Baio G, Martin A, Paly VF, Risebrough N, Halpin DMG, Singh D, Wise RA, Han MK, Martinez FJ, Criner GJ, Martin N, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1633-1642
Published Date: 25 July 2022
Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England
Sansbury LB, Lipson DA, Bains C, Anley GA, Rothnie KJ, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:415-426
Published Date: 3 March 2022
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3105-3118
Published Date: 13 November 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial
Bjermer L, Boucot IH, Maltais F, Kerwin EM, Naya IP, Tombs L, Jones PW, Compton C, Lipson DA, Vogelmeier CF
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1939-1956
Published Date: 28 June 2021
Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
Barnes NC, Singh D, Lipson DA
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1299-1301
Published Date: 10 May 2021
Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice
Sansbury LB, Bains C, Lipson DA, Ismaila AS, Landis SH
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1255-1264
Published Date: 6 May 2021
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
Vogelmeier CF, Naya IP, Maltais F, Bjermer L, Kerwin EM, Tombs L, Jones PW, Compton C, Lipson DA, Boucot IH
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1215-1226
Published Date: 3 May 2021
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, Jones PW, Martin N, Weiss G, Halpin DMG
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:499-517
Published Date: 1 March 2021
Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study
Zhong N, Zheng J, Lee SH, Lipson DA, Du X, Wu S
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:809-819
Published Date: 17 April 2020
The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2849-2861
Published Date: 6 December 2019